The global leader in rabies vaccines, the serum-free iterative rabies vaccine of AIM Vaccine has submitted a pre-application for marketing registration

Zawya

HONG KONG SAR –  Media OutReach Newswire – 18 November 2024 – AIM Vaccine (06660.HK), the world’s second largest supplier of rabies vaccines, announced on 17th November that The pre-application for marketing registration of the iterative serum-free rabies vaccine independently developed by the Company has been submitted to the National Medical Products Administration recently. To date, there is no serum-free rabies vaccine that has been approved…

Brand Spur

The global leader in rabies vaccines, the serum-free iterative rabies vaccine of AIM Vaccine has submitted a pre-application for marketing registration - Brand Spur

HONG KONG SAR – Media OutReach Newswire – 18 November 2024 – AIM Vaccine (06660.HK), the world’s second largest supplier of rabies vaccines, announced on 17th November that The pre-application for marketing registration of the iterative serum-free rabies vaccine independently developed by the Company has been submitted to the National Medical Products Administration recently. To […]

European Business Magazine

The global leader in rabies vaccines, the serum-free iterative rabies vaccine of AIM Vaccine has submitted a pre-application for marketing registration - European Business Magazine

Hong Kong – Media OutReach Newswire – November 18, 2024 – The world’s second largest rabies vaccine supplier, Aimi Vaccine (06660.

香港 –  Media OutReach Newswire – 2024年11月18日 – 全球第二大狂犬疫苗供應商艾美疫苗（06660.HK）於11月17日發佈公告，公司研發的無血清迭代狂犬病疫苗已於近日向國家藥品監督管理局提交上市註冊預申請。截至目前，全球市場上尚未有無血清狂犬病疫苗獲批上市，艾美疫苗的無血清迭代狂犬病疫苗有望成為首個上市產品。   根據已完成揭盲的Ⅲ期臨床研究結果顯示，艾美疫苗的無血清迭代狂犬病疫苗具有良好的安全性、免疫原性和免疫持久性，達到臨床預設目標。   無血清迭代狂犬病疫苗，與目前含有血清的Vero細胞狂犬病疫苗和含有血清的人二倍體狂犬病疫苗完全不同，是一款迭代升級的產品。疫苗產品中的動物血清殘留是導致疫苗接種人群產生過敏等不良反應的重要因素之一，艾美疫苗研發的無血清狂犬病疫苗不含有動物血清，顯著提高了安全性，降低了不良反應的概率。   目前，艾美疫苗已建設完成滿足國際化標準的無血清迭代狂犬疫苗車間，並已完成商業化規模驗證生產，已具備該產品規模化生產能力。…

全球狂犬疫苗龍頭艾美疫苗無血清迭代狂犬疫苗已提交上市註冊預申請

Macau Business

The global rabies vaccine leader, Aimi Vaccine, has submitted a pre-application for market registration of its serum-free iterative rabies vaccine

HONG KONG SAR –
Media OutReach Newswire – 18 November 2024 – AIM Vaccine (06660.HK), the world’s second largest supplier of rabies vaccines, announced on 17th November that The pre-application for marketing registration of the iterative serum-free rabies vaccine independently developed by the Company has been submitted to the National Medical Products Administration recently. To date, there is no serum-free rabies vaccine that has been approved …

newspatrolling.com

Laotian Times

HONG KONG SAR - Media OutReach Newswire - 18 November 2024 - AIM Vaccine (06660.HK), the world's second largest supplier of rabies vaccines, announced on 17th November that The pre-application for marketing registration of the iterative serum-free rabies vaccine independently developed by the Company has been submitted to the National Medical Products Administration recently. To date, there is no serum-free rabies vaccine that has been approved …

The global leader in rabies vaccines, the serum-free iterative rabies vaccine of AIM Vaccine has submitted a pre-application for marketing registration

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics